AGA and Fabry disease: The therapeutics for Fabry disease that are currently on the market or in clinical studies have been developed based on the known pathogenesis, which includes changes at the genetic level, supplementation or activation of the α-galactosidase A (AGA) protein, and reduction of pathogenic substrates.Current treatments, ERTs have shown clinical benefits in managing symptoms and improving quality of life for affected individuals.